HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Topics in this section

HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Fifty years of HIV: how close are we to a cure?

    It’s half a century since the first known HIV-related death and two patients appear to have been cured of the virus. What does this mean for the 37 million still living with it?

    03 July 2019 | The Guardian

  • The Listening Project: I’ll Speak About it All Day Long (sound file)

    Two 17-year-old girls infected with HIV as babies discuss their common experience in the BBC's Listening Project, a sound archive of our modern times.

    25 April 2019 | BBC

  • Long-Acting HIV Treatment Is Coming. Our Health Care System Needs to Prepare

    New conversations are starting in HIV care as phase III trials have shown that monthly injections of cabotegravir and rilpivirine (Edurant) are non-inferior to a three-drug pill regimen. In 2018, TheBody asked a range of people living with HIV about their willingness to switch to an injectible, and most had mixed feelings. But even if there's widespread interest in this new way of taking antiretroviral therapy (and most likely also prevention, not too far away), it's important to consider not just the willingness of people to move to this new form of treatment, but whether health care systems and providers in the U.S. are ready to support this innovation.

    16 April 2019 | The Body Pro

  • Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

    Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

    05 April 2019 | MedPage Today

  • Curing HIV just got more complicated. Can CRISPR help?

    Antiretroviral (ARV) drugs have turned HIV infection from a death sentence to a chronic condition. In most people the drugs routinely tamp HIV levels so low that standard tests find no virus in blood samples. But inexplicably, in about 10% of infected people HIV remains easily detectable in the blood even though they take their daily pills and are not saddled with drug-resistant mutants of the virus.

    18 March 2019 | Science

  • Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

    Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

    30 January 2019 | Positively Aware

  • Six advantages of dolutegravir

    Dolutegravir is a critically important antiretroviral medicine that is set to become the backbone of South Africa and many other countries’ HIV programmes. While the drug has recently made headlines because of a potential safety risk, most of what we know about the medicine indicates that it represents an important improvement over existing medicines.

    28 January 2019 | Spotlight SA

  • Dolutegravir- why new does not automatically mean better

    As has been previously reported by Spotlight, a new and exciting anti-retroviral, dolutegravir, is soon to become widely available in South Africa. Whilst its very real advantages have been extensively reported, the potential disadvantages have received relatively little attention.

    25 January 2019 | Spotlight

  • HIV care is threatened by proposed changes to Medicare Part D

    Optimal HIV care includes early and uninterrupted access to effective antiretroviral medications. Proposed changes to Medicare Part D threatens that.

    25 January 2019 | STAT

  • FDA To Consider Pifeltro, Delstrigo as HIV Switch-On Therapies

    The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

    23 January 2019 | MD Magazine
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.